-
公开(公告)号:US20240140937A1
公开(公告)日:2024-05-02
申请号:US18520638
申请日:2023-11-28
Applicant: Pfizer Inc.
Inventor: Markus Boehm , Shawn Cabral , Matthew S. Dowling , Kentaro Futatsugi , Kim Huard , Esther Cheng Yin Lee , Allyn T. Londregan , Jana Polivkova , David A. Price , Qifang Li
IPC: C07D405/14 , A61K31/506 , A61K45/06 , C07D401/14 , C07D409/14
CPC classification number: C07D405/14 , A61K31/506 , A61K45/06 , C07D401/14 , C07D409/14 , A61P3/06
Abstract: Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.
-
公开(公告)号:US10934279B2
公开(公告)日:2021-03-02
申请号:US16436311
申请日:2019-06-10
Applicant: Pfizer Inc.
Inventor: Gary Erik Aspnes , Scott W. Bagley , John M. Curto , David James Edmonds , Mark E. Flanagan , Kentaro Futatsugi , David A. Griffith , Kim Huard , Yajing Lian , Chris Limberakis , Allyn T. Londregan , Alan M. Mathiowetz , David W. Piotrowski , Roger B. Ruggeri
IPC: C07D405/12 , C07C53/06 , C07C53/10 , C07C215/40 , C07D405/14 , C07D413/14 , C07D471/04
Abstract: Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
-
公开(公告)号:US20210047298A1
公开(公告)日:2021-02-18
申请号:US17085534
申请日:2020-10-30
Applicant: Pfizer Inc.
Inventor: Gary Erik Aspnes , Scott W. Bagley , John M. Curto , Matthew S. Dowling , David Edmonds , Mark E. Flanagan , Kentaro Futatsugi , David A. Griffith , Kim Huard , Gajendra Ingle , Wenhua Jiao , Chris Limberakis , Alan M. Mathiowetz , David W. Piotrowski , Roger B. Ruggeri
IPC: C07D401/14 , A61K31/496 , A61K31/4545 , C07D487/04 , A61P3/00 , A61P15/10 , A61P17/06 , A61P9/10 , A61P19/06 , A61P25/28 , A61P25/30 , A61P43/00 , A61P1/16 , A61P25/02 , A61P3/04 , A61P19/02 , A61P3/10 , A61P13/12 , A61P25/18 , A61P1/00 , A61P15/00 , A61P25/16 , C07D405/14 , C07D413/14 , C07D471/04
Abstract: Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, 7-aza- and 4,7-diaza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
-
公开(公告)号:US20200377482A1
公开(公告)日:2020-12-03
申请号:US16999295
申请日:2020-08-21
Applicant: Pfizer Inc.
Inventor: Matthew Dowling , Dilinie Fernando , Kentaro Futatsugi , Kim Huard , Thomas Victor Magee , Brian Raymer , Andre Shavnya , Aaron Smith , Benjamin Thuma , Andy Tsai , Meihua Tu
IPC: C07D403/14 , A61K31/403 , C07D401/04 , C07D401/14 , C07D403/04
Abstract: Provided herein are substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
-
公开(公告)号:US20190382388A1
公开(公告)日:2019-12-19
申请号:US16535616
申请日:2019-08-08
Applicant: Pfizer Inc.
Inventor: Gary Erik Aspnes , Scott W. Bagley , John M. Curto , David James Edmonds , Mark E. Flanagan , Kentaro Futatsugi , David A. Griffith , Kim Huard , Yajing Lian , Chris Limberakis , Allyn T. Londregan , Alan M. Mathiowetz , David W. Piotrowski , Roger B. Ruggeri
IPC: C07D405/12 , C07D405/14 , C07C53/10 , C07D471/04 , C07C215/40 , C07C53/06 , C07D413/14
Abstract: Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
-
公开(公告)号:US20190119255A1
公开(公告)日:2019-04-25
申请号:US16220184
申请日:2018-12-14
Applicant: Pfizer Inc.
Inventor: Gary Erik Aspnes , Scott W. Bagley , John M. Curto , Matthew S. Dowling , David Edmonds , Mark E. Flanagan , Kentaro Futatsugi , David A. Griffith , Kim Huard , Gajendra Ingle , Wenhua Jiao , Chris Limberakis , Alan M. Mathiowetz , David W. Piotrowski , Roger B. Ruggeri
IPC: C07D401/14 , A61K31/4545 , A61P43/00 , A61P1/16 , A61P25/02 , A61P3/04 , A61P19/02 , A61P3/10 , A61P13/12 , A61P25/18 , A61P1/00 , A61P15/00 , A61P25/16 , C07D405/14 , C07D471/04 , A61P15/10 , A61P3/00 , C07D487/04 , C07D413/14 , A61P17/06 , A61P9/10 , A61P19/06 , A61P25/28 , A61P25/30 , A61K31/496
Abstract: Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, 7-aza- and 4,7-diaza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
-
公开(公告)号:US09738626B2
公开(公告)日:2017-08-22
申请号:US14970930
申请日:2015-12-16
Applicant: Pfizer Inc.
Inventor: Kevin Bahnck , Daniel Canterbury , David James Edmonds , Kentaro Futatsugi , Esther Cheng Yin Lee , Elnaz Menhaji-Klotz , Jana Polivkova , Robert Vernon Stanton
IPC: C07D401/14
CPC classification number: C07D401/14
Abstract: Provided herein are antagonists of prostaglandin EP3 receptor, processes to make said antagonists, and methods comprising administering said antagonists to a mammal in need thereof.
-
公开(公告)号:US20160176851A1
公开(公告)日:2016-06-23
申请号:US14970930
申请日:2015-12-16
Applicant: Pfizer Inc.
Inventor: Kevin Bahnck , Daniel Canterbury , David James Edmonds , Kentaro Futatsugi , Esther Cheng Yin Lee , Elnaz Menhaji-Klotz , Jana Polivkova , Robert Vernon Stanton
IPC: C07D401/14
CPC classification number: C07D401/14
Abstract: Provided herein are antagonists of prostaglandin EP3 receptor, processes to make said antagonists, and methods comprising administering said antagonists to a mammal in need thereof.
-
公开(公告)号:US09296745B2
公开(公告)日:2016-03-29
申请号:US14384508
申请日:2013-03-26
Applicant: Pfizer Inc.
Inventor: Kay Ahn , Markus Boehm , Shawn Cabral , Philip A. Carpino , Kentaro Futatsugi , David Hepworth , Daniel W. Kung , Suvi Orr , Jian Wang
IPC: C07D471/04 , A61K45/06 , C07D487/04 , C07D519/00 , A61K31/437 , A61K31/506 , A61K31/52 , A61K31/5377 , A61K31/538
CPC classification number: C07D471/04 , A61K31/437 , A61K31/506 , A61K31/52 , A61K31/5377 , A61K31/538 , A61K45/06 , C07D487/04 , C07D519/00
Abstract: Derivatives of purine, 3H-imidazo[4,5-b]pyrimidine and 1H-imidazo[4,5-d]pyrazine of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.
Abstract translation: 抑制二酰基甘油酰基转移酶2(DGAT2)活性的式I的嘌呤衍生物,3H-咪唑并[4,5-b]嘧啶和1H-咪唑并[4,5-d]吡嗪及其在治疗疾病中的用途 本文描述了与动物相连的动物。
-
公开(公告)号:US20240132483A1
公开(公告)日:2024-04-25
申请号:US18513752
申请日:2023-11-20
Applicant: Pfizer Inc.
Inventor: Gary Erik Aspnes , Scott W. Bagley , Edward L. Conn , John M. Curto , David J. Edmonds , Mark E. Flanagan , Kentaro Futatsugi , David A. Griffith , Kim Huard , Chris Limberakis , Alan M. Mathiowetz , David W. Piotrowski , Roger B. Ruggeri
IPC: C07D405/14 , C07D401/14 , C07D403/14 , C07D413/14 , C07D471/04
CPC classification number: C07D405/14 , C07D401/14 , C07D403/14 , C07D413/14 , C07D471/04
Abstract: Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
-
-
-
-
-
-
-
-
-